Heron therapeutics, inc. /de/ (HRTX)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Net product sales

139,742

145,942

139,703

116,903

97,521

77,488

58,697

47,469

38,702

30,767

21,993

13,421

4,911

1,279

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

646

997

1,527

0

0

0

Cost of product sales

57,279

61,619

57,317

47,698

39,341

27,512

17,278

10,753

6,535

4,588

3,285

2,234

1,221

35

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

161,304

167,382

158,996

154,709

143,443

140,032

147,898

146,321

144,759

138,582

120,330

121,728

120,417

103,125

89,883

73,882

62,771

61,183

59,115

59,605

57,709

54,833

48,992

40,477

37,004

32,516

29,314

26,724

18,985

15,174

12,877

12,180

10,395

8,207

6,893

5,854

0

0

0

General and administrative

38,671

37,897

36,761

35,452

31,883

29,263

26,690

25,864

25,840

25,554

25,281

24,152

22,741

21,366

22,073

20,867

20,175

18,395

8,388

8,483

8,913

11,020

19,906

22,132

22,023

21,941

19,939

15,919

12,829

8,657

6,444

5,176

4,372

3,501

2,683

3,858

0

0

0

Sales and marketing

81,240

89,764

89,301

88,605

79,489

64,604

61,330

58,578

58,817

56,601

52,568

51,198

47,434

47,668

43,216

35,180

26,931

17,347

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

338,494

356,662

342,375

326,464

294,156

261,411

253,196

241,516

235,951

225,325

201,464

199,312

191,813

172,194

155,172

129,929

109,877

96,925

85,360

81,822

77,599

74,561

68,898

62,609

59,027

54,457

49,253

42,643

31,814

23,831

19,321

17,356

14,767

11,708

9,576

9,712

0

0

0

Loss from operations

-198,728

-210,694

-202,646

-209,573

-196,647

-183,937

-194,513

-194,047

-197,249

-194,558

-179,471

-185,891

-186,902

-170,915

-155,172

-129,929

-109,877

-96,925

-85,360

-81,822

-77,599

-74,561

-68,898

-62,609

-59,027

-54,457

-49,253

-42,643

-31,814

-23,831

-19,321

-17,356

-14,516

-11,062

-8,579

-8,185

0

0

0

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

2,664

0

0

0

-

-

0

0

-

-

-

-

828

1,621

1,217

867

605

-449

-316

-433

-373

-327

-265

0

0

0

Gain on sale of royalty interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Other income, net

-375

158

2,965

5,141

3,767

1,804

5,630

1,644

717

-38

0

0

0

-

-

-

-

-

0

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other income (expense), net

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-24,430

-19,756

-15,310

0

-

0

0

-

0

0

Gain from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

Loss from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

Loss from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-319

-156

0

0

0

Net loss

-193,316

-204,749

-196,388

-201,139

-189,587

-178,840

-191,771

-195,291

-199,420

-197,484

-182,957

-189,600

-190,027

-173,143

-156,422

-130,585

-110,466

-97,591

-86,973

-83,495

-79,399

-76,367

-69,787

-63,466

-59,868

-55,283

-48,976

-42,224

-31,380

-23,348

-19,872

-17,953

-15,316

-11,814

-9,225

-8,606

0

0

0

Other comprehensive income:
Unrealized gains on short-term investments

672

172

145

173

78

-77

-42

-19

-12

7

17

-5

-31

23

-17

-1

1

-40

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-192,644

-204,577

-196,243

-200,966

-189,509

-178,917

-191,813

-195,310

-199,432

-197,477

-182,940

-189,605

-190,058

-173,120

-156,439

-130,586

-110,465

-97,631

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from continuing operations (in Dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1.94

-0.02

-0.02

-0.02

-1.80

-0.02

-0.05

-0.03

-0.04

-0.09

Basic and diluted net loss per share

-0.57

-0.65

-0.42

-0.63

-0.80

-0.63

-0.49

-0.54

-0.81

-1.08

-0.77

-0.80

-1.00

-1.23

-1.24

-1.17

-0.92

-0.88

-0.63

-0.74

-0.70

-0.69

-0.66

-0.78

-0.74

-0.72

-0.84

-1.01

-0.85

-1.85

-0.02

-0.02

-0.02

-1.85

-0.02

-0.05

-0.04

-0.04

-0.09

Shares used in computing basic and diluted net loss per share

90,409

89,209

79,940

79,548

78,419

78,285

77,811

71,952

64,724

57,663

54,176

53,791

50,530

39,310

39,113

37,048

36,229

36,124

35,773

31,035

29,392

29,320

29,004

24,266

23,686

18,738

15,375

15,285

15,254

-425,842

274,488

200

200,046

-

-

-

-

-

-

Weighted-average common shares used to compute basic and diluted net loss per share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

198

40,016

39

-

-

Shares used to compute basic and diluted net loss per share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

39,507

39,493